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ABSTRACT 
Objective: To assess Quality of life (QoL) and its associated factors in people living with HIV/AIDS (PLWHA) who taking highly active antiretroviral 
therapy (HAART) in Wangaya Hospital in Denpasar, Bali, Indonesia. 
Methods: A cross-sectional study was conducted during February 2019 to January 2020 at Wangaya Hospital in Denpasar, Bali, Indonesia. QoL was 
assessed using the five-level version of the EuroQol five-dimensional questionnaire (EQ-5D-5L), EQ-5D index value, and the EuroQol visual analogue 
scale (EQ-VAS). The data was analyzed using Statistical Package for Social Science (SPSS) software package version 26.0. Bivariate analysis was 
tested using the cross-tabulation Gamma, Kruskal-Wallis and post hoc Mann-Whitney test. P value<0.05 was considered as statistically significant. 
Results: A total of 584 PLWHA took HAART for at least 3 mo. The median index value and EQ-VAS were 1.0 (range-0.514–1.0) and 100.00 (range 
30-100), respectively. Most patients had problems in ‘anxiety/depression’ and ‘pain/discomfort’ domains. Predictors of better QoL included men, 
married, good adherence, and treatment duration>24 mo (p<0.05). Predictor of poorer QoL included an advanced HIV clinical stage(p=0.001). 
Conclusion: The QoL scores of PLWHA receiving HAART in our study were high; hence the QoL of PLWHA was good. The good QoL can be taken as 
the goal for HIV treatment in order to have a successful HAART therapy. 
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INTRODUCTION 
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency 
Syndrome (AIDS) is still a major health issue worldwide [1]. People 
living with HIV/AIDS (PLWHA) often appears with many 
comorbidities and stigma from their community [2-4]. PLWHA must 
face the disease caused by HIV infection itself or iatrogenic due to the 
treatment [5]. Hence, HIV/AIDS gives an increasing health burden that 
causing several socioeconomic problems for the patient, family, 
community, and government [1-2]. In 2018, approximately 37.9 
million people living with HIV infection and 62% of PLWHA in middle-
low income countries have received HAART [1]. Based on HIV/AIDS 
data in Indonesia 2019, there are 349.882 HIV cases and 117.064 AIDS 
cases from 1987 to June 2019 [6]. Most of PLWHA are in the 
productive age, which is 25-49 y (71.1%) [6, 7]. Not all PLWHA in 
Indonesia has received HAART. Only 33% PLWHA received HAART 
routinely and the dropout rate is still high (23%) [6].  
In the era of HAART, the mortality rate of PLWHA has decreased and 
made it a managable or controllable chronic disease [1, 8-10]. HAART 
is a long-life treatment; therefore, outcome monitoring is needed to 
assess the effectiveness and the quality of health care system. HAART 
aims are not only to increase survival but also to make PLWHA able to 
carry out daily life well. QoL is an important outcome indicator in 
assessing the impact and the quality of the health care system, making 
decision, and treatment evaluation [11-16]. QoL is defined as a 
subjective multidimensional evaluation of one’s function and his well-
being in everyday life [17-21]. WHO defines the quality of life as an 
‘individual’ perception of their position in life, in the context of the 
culture and value system in which they live and their relation to their 
goals, standards, hopes, and concerns [22-24]. 
A study from China reported that age, educational state, marriage 
state, occupational state, CD4+cell count, HIV treatment state, WHO 
clinical stage had a significant association with QoL of PLWHA [25]. 
Several factors are known to be related to QoL of PLWHA. 
Sociodemographic characteristics such as male sex, younger age, 
higher socioeconomic status, and having a job are associated with a 
better life quality [26-30]. Lower HIV viral load, higher CD4+cell 
counts, fewer HIV symptoms, indicate better clinical/immunological 
indicators of life quality [27-36]. 
This study assesses QoL of PLWHA who were taking HAART and the 
factors related with QoL outcomes from HAART at Merpati Clinic, 
Wangaya Hospital in Denpasar, Bali, Indonesia. 
MATERIALS AND METHODS 
Study population and design 
A hospital-based cross-sectional study was conducted among 584 
adult PLWHA (aged ≥ 17 y) taking HAART for at least 3 mo at 
Merpati Clinic, Wangaya Hospital in Denpasar, Bali, Indonesia. All 
PLWHA who came for control routinely during February 2019 to 
January 2020 were the participants in this study.  
The comprehensive care support treatment would be provided to all 
adult PLWHA during the control regularly every 30 d and who were 
given written informed consent. The participants were interviewed 
about the socio-demographic characteristics. The socio-demographic 
data included age, sex, education status, marital status, and 
employment status. The clinical characteristics included HIV 
transmission route, last CD4+cell count, HIV clinical stage, treatment 
compliance, duration of HIV infection, duration of HAART, and the 
adherence to HAART.  
The adherence was measured by the pill counts taken based on a 30 
d recall. The adherence index was calculated by the formula:  
100 x 
days) 30(for  prescribed drugs ofnumber  Total
days) 30(for  taken drugs ofnumber  Total
 
Participants with ≥ 95% of adherence were considered as having 
good adherence (Good adherence to HAART was defined as taking 
HAART for 30 d more than 95%) [37, 38]. 
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Life quality assessment was done through interviews using an 
instrument issued by The EuroQoL Group called the EuroQoL–5 
Dimensions–5 Levels (EQ-5D-5L) [37, 39]. This instrument consisted 
of five dimensions, including mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression. This instrument has been widely 
used in various studies on health-related QoL (HRQOL) and has been 
made in various language versions, one of which is Indonesian. EQ-5D-
5L provides a descriptive profile and assessment of a single index for 
current health status. Each dimension was divided into five-level 
problems, there are ‘no problems, ‘little problems, ‘moderate 
problems, ‘severe problems’, and ‘unable to do/extreme problems’. 
Index value was calculated using EQ-5D index value calculator for 
Colombia [40]. There was no index value calculator for Indonesia. 
Furthermore, there was the EQ-VAS that could assess the number of 
health felt by patients on that day with a range of values from 0-100, 
where zero was the worst condition felt by patients. Before being 
interviewed, we gave explanation to all subjects about the purpose of 
the study and the subjects had to agree to be interviewed. All subjects 
were informed that all data we obtained would be kept confidential.  
Statistical analysis 
The collected data was processed using the Statistical Package for 
Social Science (SPSS) software package version 26.0. Patient 
characteristics were presented in percentage and median values. 
QoL was presented in percentage, average value, and range. 
Bivariate analysis was tested using the cross-tabulation Gamma, 
Kruskal-Wallis and post hoc Mann-Whitney test. P value<0.05 was 
considered as statistically significant. 
Ethical clearance  
The study procedure was approved by the Ethical Committee of 
Wangaya Hospital in Denpasar Bali Indonesia with register number: 
05/RSUDW/litbang/2019). The study was conducted following the 
Declaration of Helsinki. Written informed consent was obtained 
from all the participants. 
RESULTS 
A total of 584 participants (PLWHA) taking HAART for at least 3 mo 
were willing to be interviewed in this study. Most of PLWHA were 
male 333 (57%). The median of age was 39 y (age range 17-79 y) 
with the highest percentage of patients were 30-39 y. Most 
participants had a high school education (60.8%), married (69.2%), 
and employed (89.6%). The participants were at symptomatic HIV 
stage (76.7%), HIV transmission route non-intravenous drug user 
(99.5%), median CD4+cell count 305.50 cells/mm3with the highest 
range of CD4+cell counts>200 cells/mm3 (47.6%), and the good 
adherence of HAART (97.4%). The median duration of HIV infection 
was 47 mo. The median duration of HAART treatment was 43 mo, 
with most participants had treatment for more than 24 mo (67.2%). 
Complete socio-demographic and clinical data of the participants can 
be seen in table 1. 
 
Table 1: Socio-demographic and clinical characteristics of participants and the association with quality of life 
Variables N % EQ-VAS Index value 
p-value p-value 
All participants  584 100.0   
Gender     
- Male 333 57.0 0.106 0.047* 
- Female 251 43.0   
Median of age (years) 39.0    
Age     
- <30 y 97 16.6 0.747 0.731 
- 30-39 y 222 38.0   
- 40-49 y 162 27.7   
- 50-59 y 77 13.2   
- ≥60 26 4.5   
Educational status     
- Elementary school 49 8.4 0.455 0.406 
- Junior high school  102 17.5   
- Senior high school 355 60.8   
- Academy/University 78 13.4   
Marital status     
- Single  404 69.2 0.027* 0.023* 
- Married  114 19.5   
- Divorced or widowed 66 11.3   
Occupation     
- Yes 523 89.6 0.419 0.516 
- No 61 10.4   
Transmission routes     
- IV drug user 3 0.5 0.417 0.428 
- Non-IV drug user 581 99.5   
Median CD4+cell count (cells/mm3) 305.50    
CD4+cell count (cells/mm3)     
- ≤200 142 24.3 0.167 0.160 
- 201-349 102 17.5   
- 350-499 90 15.4   
- ≥500 86 14.7   
- Missing data 164 28.1   
WHO clinical stage     
- Asymptomatic  63 10.8 0.001* 0.001* 
- Symptomatic  448 76.7   
- AIDS 73 12.5   
Adherence of HAART     
- Good  569 97.4 0.005* 0.002* 
- Poor  15 2.6   
Median of HIV infection duration (months) 47.0    
Median of treatment duration (months) 43.0    
Treatment duration     
- ≤24 mo 197 33.7 0.001* 0.003* 
- 25-48 mo 138 23.6   
- ≥49 mo 249 42.6   
Abbreviation: HAART= highly active antiretroviral therapy, Note *significant p<0.05  
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Table 2: EQ-5D-5L profile of participant (PLWHA) by different disease stage 
Dimension Asymptomatic Symptomatic AIDS all p-value 
Mobility     <0.00* 
 No problems 63 (100.0) 445 (99.3) 64 (87.7) 572 (97.9)  
 Slight problems 0 (0.0) 1 (0.2) 2 (2.7) 3 (0.5)  
 Moderate problems 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
 Severe problems 0 (0.0) 0 (0.0) 3 (4.1) 3 (0.5)  
 Unable to 0 (0.0) 2 (0.4) 4 (5.5) 6 (1.0)  
Self-care     <0.00* 
 No problems 63 (100.0) 446 (99.6) 66 (90.4) 575 (98.5)  
 Slight problems 0 (0.0) 0 (0.0) 1 (1.4) 1 (0.2)  
 Moderate problems 0 (0.0) 0 (0.0) 1 (1.4) 1 (0.2)  
 Severe problems 0 (0.0) 0 (0.0) 3 (4.1) 3 (0.5)  
 Unable to 0 (0.0) 2 (0.4) 2 (2.7) 4 (0.7)  
Usual activity     <0.00* 
 No problems 63 (100.0) 446 (99.6) 64 (87.7) 573 (98.1)  
 Slight problems 0 (0.0) 0 (0.0) 4 (5.5) 4 (0.7)  
 Moderate problems 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
 Severe problems 0 (0.0) 1 (0.2) 4 (5.5) 5 (0.9)  
 Unable to 0 (0.0) 1 (0.2) 1 (1.4) 2 (0.3)  
Pain/Discomfort     <0.00* 
 No problems 63 (100.0) 426 (95.1) 53 (72.6) 542 (92.8)  
 Slight pain 0 (0.0) 15 (3.3) 11 (15.1) 26 (4.5)  
 Moderately pain 0 (0.0) 5 (1.1) 2 (2.7) 7 (1.2)  
 Severe pain 0 (0.0) 1 (0.2) 4 (5.5) 5 (0.9)  
 Extreme pain 0 (0.0) 1 (0.2) 3 (4.1) 4 (0.7)  
Anxiety/depression     0.002* 
 No problems 57 (90.5) 413 (92.2) 52 (71.2) 552 (89.4)  
 Slightly  4 (6.3) 23 (5.1) 11 (15.1) 38 (6.5)  
 Moderately  2 (3.2) 10 (2.2) 7 (9.6) 19 (3.3)  
 Severely  0 (0.0) 2 (0.4) 3 (4.1) 5 (0.9)  
 Exteremely  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
 Note *significant p<0.05  
 
Quality of life for participants (plwha)  
Table 2 shows the profile of QoL among participants (PLWHA) based 
on different clinical stages of HIV. We found the highest proportion 
of patients reporting ‘no problem’ on the ‘self-care’ dimension. Only 
a small proportion of participants were reported ‘very poor’ state, 
The highest proportion of ‘very poor’ state was in the ‘mobility’ 
dimension. In addition, it was found that the clinical stage of HIV was 
significantly related to the five dimensions of QoL of PLWHA in this 
study. Median of EQ-VAS was 100.0 (range 30–100). Median of EQ-
5D index value was 1.0 (range-0.514–1.0). Table 1 shows the 
association between variable groups and EQ-VAS or EQ-5D index 
value. 
DISCUSSION 
The QoL of PLWHA, who came into Merpati Clinic at Wangaya 
Hospital in Denpasar, Bali, Indonesia are assessed with the EQ-5D-
5L instrument issued by the EuroQoL which consists of five 
dimensions including mobility, self-care, usual activity, 
pain/discomfort, dan anxiety/depression. Mobility is the patient’s 
ability to walk. Self-care is the patient’s ability to care for themselves 
such as bathing and dressing. Usual activity is daily activities such as 
work, study, do housework, family activities or recreation. 
Pain/discomfort is the feeling of pain/discomfort felt by the patient 
at present. Anxiety/depression is anxiety or depression/sad feeling 
felt by the patient at present. This instrument can present the EQ-
5D-5L profile, EQ-5D index value, and EQ-VAS [31]. We also assess 
the relationship between the patient’s characteristic variables with 
the EQ-5D index value and EQ-VAS. 
The socio-demographic and clinical characteristics of participants in 
this study can be seen in table 1. These findings were similar to some 
health-related QoL (HRQOL) studies in other PLWHA in various 
countries [41-43]. Based on the five EQ-5D-5L domains, the most 
domains with ‘no problem’ state in this study were self-care and 
usual activity. The results of this study are the same as two previous 
studies by Keaei M et al. in Colombia and Tran BX et al. in Vietnam 
about HRQOL in PLWHA that also use the EQ-5D-5L instrument. 
They reported the most dimensions with ‘no problem’ state were 
self-care and usual activity [40, 43]. The most domains with ‘very 
poor’ state in this study were mobility, pain/discomfort, and self-
care. The results were different from the two previous studies. The 
'very poor' state in the Keaei M et al. study was mostly in 
pain/discomfort (4.35%) and anxiety/depression (2.17%) domains, 
while Tran BX et al. study was anxiety/depression (4.5%) and usual 
activities (3.4%) [40, 43].  
Here we found, most of our participants had a ‘slight problem’ in the 
anxiety/depression (6.5%) and pain/discomfort (4.5%) domains. 
More attention is needed because PLWHA with anxiety/depression 
and pain/discomfort were reported to have poorer outcomes [41]. 
Most participants in this study were married (69.2%). Single PLWHA 
were related to better QoL in the EQ-5D index value (p=0.023) and 
EQ-VAS (p=0.027). Married PLWHA 5.7 (1.8-18.5) times more likely 
to have severe depression compared to single PLWHA (p<0.01) [25]. 
PLWHA with severe depression had significantly worse QoL by 2.7 
times, therefore, it is important for us to keep patients from falling 
into severe depression [25]. The presence of problems in the 
anxiety/depression domain indicated the need for psychological 
support for PLWHA, especially the female during HAART treatment 
[41, 44]. Social support is also important because it can increase the 
QoL [28]. EQ-5D-5L profile in this study is significantly associated 
with HIV clinical stage (p<0.05) (table 2). 
The median EQ-5D index value and EQ-VAS obtained were 1.0 
(range-0.514–1.0) and 100 (range 30–100), respectively. The 
Columbia study also reported a good QoL with the mean EQ-5D 
index value and EQ-VAS of PLWHA in that study were 0.85±0.21 and 
84.38±14.27, respectively [40]. Another study in Vietnam reported a 
lower QoL with EQ-5D index value of 0.65 (SD=0.27) 95% CI 0.63-
0.67 and mean VAS 70.3 (SD=19) 95% CI 69.2-71.5, respectively 
[43]. However, another study in Ghana reported QoL on the question 
of health satisfaction of PLWHA. They mostly appraised their health 
as excellent (77.85%) and (6.96%) as good [44]. 
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The factors that significantly associated with QoL should have a p-
value<0.05 on both with EQ-5D index values and EQ-VAS. Our study 
revealed that male sex is related to better QoL in the EQ-5D index 
value (p=0.047), but not to EQ-VAS (p=0.106). These findings are 
similar to the previous study that men have a higher EQ-5D index 
value than women (p = 0.002); however, not significant for EQ-VAS 
(p = 0.842) [41]. 
Factors significantly associated with QoL both with EQ-5D index 
values and EQ-VAS included marital status, HIV clinical stage, 
treatment adherence, and duration of treatment (table 1). In the 
marital status variable, married participants had higher EQ-VAS 
scores and EQ-5D index values compared to unmarried patients 
(p=0.011). This was slightly different from previous studies that 
reported unmarried/single PLWHA had better QOL [43, 45]. 
In the variable HIV clinical-stage, participants with AIDS clinical 
stage have lower EQ-VAS scores and EQ-5D index values compared 
to asymptomatic and symptomatic stages, p=0.001 and p=0.001, 
respectively. These findings are similar to some previous studies, in 
which the factors that influence the poorer quality of life are more 
advanced HIV clinical stages [42-46]. Only a few participants in our 
study are in AIDS clinical stage (12.5%).  
In the treatment adherence variable, participants with good 
treatment adherence have higher EQ-VAS scores and EQ-5D index 
values compared to poor treatment adherence, p=0.005 and 
p=0.002, respectively. Most participants in our study have good 
adherence to HAART (97.4%). Participants with a treatment 
duration of HAART less than 24 mo have lower EQ-VAS scores 
compared to participants who have been treated for 25-48 mo and 
more than 49 mo, p=0.001 and p=0.005, respectively. They also have 
lower EQ-5D index values compared to participants who have been 
treated for 25-48 mo and more than 49 mo, p=0.011 and p=0.003, 
respectively. These findings are similar to some previous studies 
that the duration of treatment for more than 24 mo has a better 
quality of life [42, 44].  
In this study, age, educational status, employment status, HIV 
transmission route, and CD4+cell count are not statistically 
significant related to QoL (table 1). These findings are similar to 
some previous studies [28,44,48]. However, according to some 
studies, higher education, being employed, CD4+cell counts 200 
cells/mm3 or more are associated with better QoL [42-45].  
The QoL of participants (PLWHA) receiving HAART therapy are very 
important to evaluate and it as a reflection of the quality and 
effectiveness of healthcare services, medication adherence, and 
outcomes. Overall, the QoL of PLWHA in this study is good. The 
associated factors are: gender (most of the participants are male), a 
higher education status, married, employed, a good treatment 
adherence, CD4+cell count above than 200 cells/mm3, and treatment 
duration more than 24 mo. 
CONCLUSION 
The QoL of PLWHA on HAART in this study was generally good. Our 
study demonstrated the relationship between male sex, married, 
good adherence, and treatment duration>24 mo to a better QoL. The 
advanced HIV clinical stage of PLWHA showed a relationship to poor 
QoL. The regular assessment of HRQOL among PLWHA in the 
monitoring and evaluation of HAART treatment is necessary. Good 
QoL can be taken as the goal for HIV treatment to have a successful 
HAART therapy. 
ABBREVIATION 
CD4+= Cluster differentiation 4+, EQ-5D-5L = EuroQol five-
dimensional questionnaire, EQ-VAS= EuroQol visual analogue scale, 
HAART = Highly Active Anti Retroviral Therapy, HIV = human 
immunodeficiency virus, HRQOL = health-related QoL, PLWHA = 
People living with HIV/AIDS, QoL = Quality of Life  
STUDY LIMITATIONS 
This study had several limitations. First, this study was only a single-
center study. Second, we used a cross-sectional study design so it is not 
enough to prove the causal relationship. The strengths of this study were 
a large number of patients and they had the authority to assess the 
condition of their health, thereby reducing bias in the assessment. 
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